Teva Pharmaceuticals USA, Inc., v. GlaxoSmithKline, LLC

Petition for certiorari denied on May 15, 2023

Docket No.	Argument	Opinion	Vote	Author	Term
22-37	N/A	N/A	N/A	N/A	OT 2022

Issue: Whether a generic drug manufacturer's FDA-approved label that carves out all of the language the brand manufacturer has identified as covering its patented uses can be held liable on a theory that its label still intentionally encourages infringement of those carved-out uses.

SCOTUSblog Coverage

Congressional redistricting, patent infringement, arbitration, and the Armed Career Criminal Act (John Elwood, May 11, 2023)
Court agrees to hear nine new cases, including challenge to tech companies immunity under Section 230 (Amy Howe, October 3, 2022)
Justices asked to strengthen the right to earn a living (Kalvis Golde, July 30, 2022)

Date	Proceedings and Orders (key to color coding)
04/29/2022	Application (21A677) to extend the time to file a petition for a writ of certiorari from May 12, 2022 to July 11, 2022, submitted to The Chief Justice.
05/03/2022	Application (21A677) granted by The Chief Justice extending the time to file until July 11, 2022.
07/11/2022	Petition for a writ of certiorari filed. (Response due August 12, 2022)
07/25/2022	Motion to extend the time to file a response from August 12, 2022 to September 12, 2022, submitted to The Clerk.
07/26/2022	Motion to extend the time to file a response is granted and the time is extended to and including September 12, 2022.
08/10/2022	Brief amici curiae of 42 Professors of Law, Economics, Business, and Medicine filed.
08/12/2022	Brief amicus curiae of Alvotech filed.
08/12/2022	Brief amicus curiae of Mylan Pharmaceuticals Inc. filed.
08/12/2022	Brief amicus curiae of Association for Accessible Medicines filed.
08/19/2022	Brief of respondents GlaxoSmithKline LLC, et al. in opposition filed.
09/07/2022	DISTRIBUTED for Conference of 9/28/2022.
09/07/2022	Reply of petitioner Teva Pharmaceuticals USA, Inc. filed. (Distributed)
10/03/2022	The Solicitor General is invited to file a brief in this case expressing the views of the United States.
03/29/2023	Brief amicus curiae of United States filed.
04/11/2023	Supplemental brief of respondents GlaxoSmithKline LLC, et al. filed. (Distributed)
04/12/2023	DISTRIBUTED for Conference of 4/28/2023.
05/08/2023	DISTRIBUTED for Conference of 5/11/2023.
05/15/2023	Petition DENIED. Justice Kavanaugh would grant the petition for a writ of certiorari.